ALCL
MCID: ANP001
MIFTS: 61

Anaplastic Large Cell Lymphoma (ALCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Anaplastic Large Cell Lymphoma:

Name: Anaplastic Large Cell Lymphoma 12 20 58 29 54 15 37 17
Alcl 20 58
Cd30 Positive Anaplastic Large Cell Lymphoma 58
Ki-1 Positive Anaplastic Large Cell Lymphoma 58
Ki-1+ Anaplastic Large Cell Lymphoma 70
Anaplastic Large-Cell Lymphoma 36
Primary Systemic Alcl 58
Sacl 58

Characteristics:

Orphanet epidemiological data:

58
anaplastic large cell lymphoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050744
KEGG 36 H01601
MESH via Orphanet 45 D017728
ICD10 via Orphanet 33 C84.6 C84.7
UMLS via Orphanet 71 C0206180
Orphanet 58 ORPHA98841
UMLS 70 C0206180

Summaries for Anaplastic Large Cell Lymphoma

GARD : 20 Anaplastic large cell lymphoma (ALCL) is a rare type of Non-Hodgkins lymphoma. Lymphoma is a cancer of the lymph system, part of our immune system. Non-Hodgkins lymphoma involves abnormal growth of white blood cells, either T cells or B cells. Anaplastic large cell lymphoma is an aggressive cancer that usually involves the T-cells. Cancer cells in ALCL can be identified by their appearance under the microscope and by the presence of a tumor marker called CD30 or Ki-1. There are two types of ALCL, a type that affects mainly the skin (cutaneous ALCL) and a type that affects other body organs (systmic ALCL). Systemic ALCL also has two types, ALK-positive (anaplastic lymphoma kinase) and ALK-negative. ALK-positive ALCL occurs more often in children and young adults. ALK-negative ALCL tends to occur in older adults. The symptoms of cutaneous ALCL include red skin lesions that break open and do not heal. Sometimes cutaneous ALCL is also found in the lymph nodes. The symptoms of systemic ALCL include fever, night sweats, and weight loss (B symptoms). The cancer can be found in the bone, soft tissue, spleen, liver and skin. The cause of ALCL is unknown. One type of ALK-negative ALCL has been associated with breast implants. ALCL is diagnosed by a biopsy of the tumor or abnormal skin and examination of the tumor cells under a microscope. Additional testing including PET scans, CT scans, MRI and a bone marrow biopsy can tell doctors if the cancer has spread to other organs.[15060 ALCL is treated using chemotherapy, and a stem-cell transplant for people with more aggressive cancer or for ALCL that has come back. In addition, there are newer treatments that target the cancer cells directly and have been very effective. In general, ALK-positive ALCL has a better long-term outlook than ALK-negative ALCL.

MalaCards based summary : Anaplastic Large Cell Lymphoma, also known as alcl, is related to breast implant-associated anaplastic large cell lymphoma and alk-positive anaplastic large cell lymphoma. An important gene associated with Anaplastic Large Cell Lymphoma is LINC01013 (Long Intergenic Non-Protein Coding RNA 1013), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Etoposide and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and t cells, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin lymphoma involving aberrant T-cells.

KEGG : 36 Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by a proliferation of large lymphoid cells, referred to as hallmark cells, with strong expression of CD30. The World Health Organization recognizes 3 entities: primary cutaneous ALCL (pcALCL), anaplastic lymphoma kinase (ALK)-positive ALCL, and, provisionally, ALK-negative ALCL. pcALCL presents in the skin and, while it may involve locoregional lymph nodes, rarely disseminates. ALK-positive ALCL, by definition overexpresses an ALK-fusion gene, typically via t(2;5)(p23;35) which fuses the ALK gene on chromosome 2 with the nucleophosmin (NPM) gene on chromosome 5, resulting in a NPM-ALK chimeric protein with constitutive tyrosine kinase activity. ALK-negative ALCLs lack ALK rearrangements and their genetic and clinical features are more variable. A subset of ALK-negative ALCLs has rearrangements at 6p25.3 involving DUSP22, a gene encoding a dual-specificity phosphatase that inhibits T-cell receptor signaling. DUSP22 rearrangements also are seen in a subset of pcALCLs.

Wikipedia : 73 Anaplastic large-cell lymphoma (ALCL) is a form of cancer. It is a type of non-Hodgkin lymphoma... more...

Related Diseases for Anaplastic Large Cell Lymphoma

Diseases in the Anaplastic Large Cell Lymphoma family:

Anaplastic Small Cell Lymphoma

Diseases related to Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 430)
# Related Disease Score Top Affiliating Genes
1 breast implant-associated anaplastic large cell lymphoma 33.2 TNFRSF8 STAT3 ALK
2 alk-positive anaplastic large cell lymphoma 33.1 TNFRSF8 STAT3 NPM1 JAK3 ALK
3 primary cutaneous anaplastic large cell lymphoma 32.7 PTPRC NPM1 MUC1 GZMB ALK
4 reticulosarcoma 32.5 TNFRSF8 PTPRC PAX5 NPM1 MUC1 GZMB
5 peripheral t-cell lymphoma 32.4 TNFRSF8 STAT3 PTPRC JAK3 GZMB ALK
6 lymphomatoid papulosis 31.9 TNFRSF8 NPM1 GZMB ALK
7 lymphoma 31.8 TNFSF8 TNFRSF8 TFG RNF213 PTPRC PAX5
8 lymphoproliferative syndrome 31.7 TNFRSF8 STAT3 PTPRC ALK
9 mycosis fungoides 31.5 TNFRSF8 STAT3 GZMB CLU ALK
10 diffuse large b-cell lymphoma 31.4 TNFRSF8 STAT3 PTPRC PAX5 ALK
11 histiocytosis 31.4 TNFRSF8 PTPRC ALK
12 breast lymphoma 31.3 TNFRSF8 ALK
13 hodgkin's lymphoma, lymphocytic-histiocytic predominance 31.3 TNFRSF8 PTPRC
14 lymphoma, hodgkin, classic 31.3 TRAF1 TNFSF8 TNFRSF8 PTPRC PAX5 JUNB
15 t-cell lymphoma, subcutaneous panniculitis-like 31.3 TNFRSF8 GZMB ALK
16 b-cell lymphoma 31.3 TRAF1 TNFRSF8 STAT3 PTPRC PAX5 NPM1
17 adult t-cell leukemia 31.3 TNFRSF8 STAT3 JAK3 CD4
18 primary cutaneous t-cell lymphoma 31.2 TNFRSF8 JUNB
19 bone lymphoma 31.2 TNFRSF8 PTPRC ALK
20 t-cell lymphoblastic leukemia/lymphoma 31.2 TNFRSF8 STAT3 PTPRC JUNB CD4
21 panniculitis 31.1 TNFRSF8 GZMB CD4
22 pediatric lymphoma 31.1 TNFRSF8 NPM1 ALK
23 sarcoma 31.1 STAT3 NPM1 MUC1 CSF1R ALK
24 lung lymphoma 31.0 TNFRSF8 PAX5
25 lymphoma, non-hodgkin, familial 30.9 TRAF1 TNFSF8 TNFRSF8 STAT3 PTPRC PAX5
26 ewing sarcoma 30.8 TNFRSF8 STAT3 PTPRC ALK
27 inflammatory myofibroblastic tumor 30.8 TFG RNF213 NPM1 MUC1 ALK ACVRL1
28 parapsoriasis 30.8 TNFRSF8 CD4
29 follicular mucinosis 30.7 TNFRSF8 CD4
30 myeloid sarcoma 30.7 PTPRC PAX5 NPM1
31 pericardial effusion 30.7 TNFRSF8 CD4 ALK
32 celiac disease 1 30.7 STAT3 PTPRC GZMB CD4
33 lymphoepithelioma-like carcinoma 30.6 TNFRSF8 MUC1 ALK
34 t-cell adult acute lymphocytic leukemia 30.6 TNFRSF8 JAK3 CD4 ALK
35 composite lymphoma 30.5 TNFRSF8 PAX5 GZMB
36 lymphoblastic lymphoma 30.5 TNFRSF8 PTPRC PAX5 CD4
37 lymphoma, mucosa-associated lymphoid type 30.5 TNFRSF8 PTPRC PAX5 CD4
38 tracheal lymphoma 30.5 TNFRSF8 PAX5
39 thrombocytopenia 30.5 TNFRSF8 STAT3 PAX5 NPM1 GZMB ACVRL1
40 leukemia, chronic lymphocytic 30.4 TRAF1 TNFRSF8 STAT3 PTPRC PAX5 CD4
41 mature t-cell and nk-cell lymphoma 30.4 TNFRSF8 STAT3 JAK3 GZMB CD4 ALK
42 neuroendocrine carcinoma 30.4 PTPRC PAX5 MUC1
43 leukemia, acute myeloid 30.3 TNFRSF8 STAT3 PTPRC PAX5 NPM1 JAK3
44 leukemia, acute lymphoblastic 30.2 TNFSF8 TNFRSF8 PTPRC PAX5 JAK3 CSF1R
45 alk-negative anaplastic large cell lymphoma 11.9
46 anaplastic small cell lymphoma 11.4
47 rapidly involuting congenital hemangioma 10.7
48 cutaneous t cell lymphoma 10.6
49 leukemia, t-cell, chronic 10.6
50 t-cell non-hodgkin lymphoma 10.6

Graphical network of the top 20 diseases related to Anaplastic Large Cell Lymphoma:



Diseases related to Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Anaplastic Large Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 ACVRL1 CD4 CSF1R JAK3 JUNB NPM1
2 immune system MP:0005387 9.4 CD4 CLU CSF1R JAK3 JUNB NPM1

Drugs & Therapeutics for Anaplastic Large Cell Lymphoma

Drugs for Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 285)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4 33419-42-0 36462
2
Ifosfamide Approved Phase 4 3778-73-2 3690
3
Pirarubicin Investigational Phase 4 72496-41-4
4 Etoposide phosphate Phase 4
5
Isophosphamide mustard Phase 4 100427
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
7
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
9
leucovorin Approved Phase 3 58-05-9 6006
10
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
11
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
12
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
13 Orange Approved Phase 3
14
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
15
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
16
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
17
Vinblastine Approved Phase 3 865-21-4 241903 13342
18
Mercaptopurine Approved Phase 3 50-44-2 667490
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
21
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
22
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
23
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
24
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
25
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
26
Gemcitabine Approved Phase 3 95058-81-4 60750
27
Lenograstim Approved, Investigational Phase 3 135968-09-1
28
Dalteparin Approved Phase 3 9005-49-6
29
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
30
Ofloxacin Approved Phase 3 82419-36-1 4583
31
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
32
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
33
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
34
Iron Approved Phase 3 7439-89-6 23925 29936
35
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
36
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
39
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
40
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
41
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
42
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
43 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
44 Antimetabolites Phase 3
45 Nutrients Phase 3
46 Micronutrients Phase 3
47 Gastrointestinal Agents Phase 3
48 Trace Elements Phase 3
49 Antiemetics Phase 3
50 Vitamins Phase 3

Interventional clinical trials:

(show top 50) (show all 253)
# Name Status NCT ID Phase Drugs
1 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Unknown status NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
2 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Active, not recruiting NCT01909934 Phase 4 brentuximab vedotin
4 A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
5 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
8 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
9 International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;therapeutic hydrocortisone;vinblastine sulfate
10 A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine Completed NCT00059839 Phase 3 doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;vinblastine sulfate;vincristine sulfate
11 Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab vs Observation Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
12 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
13 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
14 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
15 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
16 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
17 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
19 Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
20 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
21 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
22 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
23 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
24 A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
25 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
26 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
27 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
28 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
29 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
30 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
31 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
32 A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
33 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
34 A Phase II Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin (BSHAP) as Salvage in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00069966 Phase 2 cisplatin;cytarabine;methylprednisolone;pixantrone dimaleate
35 Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
36 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
37 Phase II Study of Vinorelbine for Children With Recurrent Anaplastic Large Cell Lymphoma Unknown status NCT03397953 Phase 2 Vinorelbine
38 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
39 Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma Completed NCT00109928 Phase 2 cisplatin;etoposide;gemcitabine;methylprednisolone
40 A Phase II Study Of Gemcitabine, Dexamethasone, And Cisplatin (GDP) In Patients With Either Hodgkin's Disease Or Aggressive Histology Non-Hodgkin's Lymphoma Which Is Relapsed Or Refractory Completed NCT00014209 Phase 2 cisplatin;dexamethasone;gemcitabine hydrochloride
41 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
42 Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Diffuse Large B-Cell Non-Hodgkin's Lymphoma That is Refractory or Relapsed After Second-Line Combination Chemotherapy Revised Title Per 03/01 SR Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Aggressive Non-Hodgkin's Lymphoma That is Refractory to or Relapsed After Second-Line Combination Chemotherapy Completed NCT00006383 Phase 2 liposomal vincristine sulfate
43 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
44 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
45 A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL) Completed NCT00006125 Phase 2 doxorubicin hydrochloride;topotecan hydrochloride
46 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
47 Phase II Study of Arsenic Trioxide (NSC #706363) in Relapsed and Refractory Intermediate and High-Grade Non-Hodgkin's Lymphoma Completed NCT00005040 Phase 2 arsenic trioxide
48 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
49 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
50 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate

Search NIH Clinical Center for Anaplastic Large Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Anaplastic Large Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Anaplastic Large Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Anaplastic Large Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Anaplastic Large Cell Lymphoma

Genetic tests related to Anaplastic Large Cell Lymphoma:

# Genetic test Affiliating Genes
1 Anaplastic Large Cell Lymphoma 29

Anatomical Context for Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Anaplastic Large Cell Lymphoma:

40
Breast, Skin, T Cells, Bone Marrow, Bone, Spleen, B Cells

Publications for Anaplastic Large Cell Lymphoma

Articles related to Anaplastic Large Cell Lymphoma:

(show top 50) (show all 5123)
# Title Authors PMID Year
1
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management. 61 20
30596216 2019
2
Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. 20 61
29279550 2017
3
Anaplastic large cell lymphoma, ALK-negative. 20 61
22789917 2013
4
C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. 61 54
20015877 2010
5
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. 61 54
20436485 2010
6
PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. 54 61
20118907 2010
7
Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. 54 61
20217288 2010
8
ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". 61 54
19695703 2010
9
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. 54 61
20179225 2010
10
Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. 54 61
20406193 2010
11
Cytomorphologic features of primary anaplastic large cell lymphoma of the psoas muscle: a case report and literature review. 61 54
19760764 2010
12
Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. 54 61
19823169 2009
13
The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. 54 61
19734424 2009
14
The spectrum of peripheral T-cell lymphomas. 61 54
19509496 2009
15
Anaplastic lymphoma kinase: signalling in development and disease. 61 54
19459784 2009
16
Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. 61 54
19289586 2009
17
Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases. 61 54
19289593 2009
18
Expression of ALK protein, mRNA and fusion transcripts in anaplastic large cell lymphoma. 61 54
19135051 2009
19
Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic simulants. 61 54
19220628 2009
20
Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. 61 54
19760074 2009
21
Primary leptomeningeal ALK+ lymphoma in a 13-year-old child. 61 54
19131793 2008
22
A rapidly progressing, fatal case of primary systemic anaplastic large cell lymphoma presenting as erythroderma--association with carbamazepine. 54 61
19265618 2008
23
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. 61 54
18974134 2008
24
[Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma]. 54 61
19176054 2008
25
Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. 54 61
18509351 2008
26
[Expression of ALK protein in large cell lymphoma with ALCL chromosome translocation in relation to prognosis]. 54 61
18549625 2008
27
AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. 54 61
18519761 2008
28
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. 54 61
18451166 2008
29
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. 61 54
18324919 2008
30
[Nuclear microarray combined with fluorescence in situ hybridization for detecting ALK gene translocation in paraffin-embedded anaplastic large cell lymphoma and its significance]. 61 54
18495593 2008
31
Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. 61 54
18275429 2008
32
CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. 61 54
18187570 2008
33
Pathobiology and molecular profiling of peripheral T-cell lymphomas. 61 54
19074096 2008
34
Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. 61 54
17965727 2008
35
The anaplastic lymphoma kinase in the pathogenesis of cancer. 61 54
18097461 2008
36
Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status. 61 54
17320171 2008
37
Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. 54 61
17681947 2007
38
Pretargeted antibody-guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma. 61 54
17655697 2007
39
Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma. 54 61
17560012 2007
40
Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. 54 61
17610208 2007
41
Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction. 61 54
17608768 2007
42
Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. 54 61
17490616 2007
43
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. 54 61
17483340 2007
44
Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma. 54 61
17488159 2007
45
Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma: A report from the children's oncology group. 54 61
17439836 2007
46
c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. 61 54
17325487 2007
47
Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. 61 54
17321986 2007
48
Identification and validation of the anaplastic large cell lymphoma signature. 54 61
17695725 2007
49
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. 54 61
17111047 2006
50
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. 61 54
17157164 2006

Variations for Anaplastic Large Cell Lymphoma

Cosmic variations for Anaplastic Large Cell Lymphoma:

9 (show top 50) (show all 216)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM89629521 SF3B1 soft tissue,liver,other,neoplasm c.2014G>T p.A672S 2:197402619-197402619 3
2 COSM87508264 NCOR1 soft tissue,liver,other,neoplasm c.3838G>T p.G1280W 17:16072202-16072202 3
3 COSM101155459 NCOR1 soft tissue,liver,other,neoplasm c.3886G>T p.G1296W 17:16072202-16072202 3
4 COSM101210927 NCOR1 soft tissue,liver,other,neoplasm c.3559G>T p.G1187W 17:16072202-16072202 3
5 COSM144457442 MSH6 soft tissue,liver,other,neoplasm c.2309G>A p.G770D 2:47803462-47803462 3
6 COSM131472690 MSH6 soft tissue,liver,other,neoplasm c.2309G>A p.G770D 2:47803462-47803462 3
7 COSM85779643 MSH6 soft tissue,liver,other,neoplasm c.3215G>A p.G1072D 2:47803462-47803462 3
8 COSM144639336 MSH6 soft tissue,liver,other,neoplasm c.119G>A p.G40D 2:47803462-47803462 3
9 COSM132100831 MSH6 soft tissue,liver,other,neoplasm c.2825G>A p.G942D 2:47803462-47803462 3
10 COSM85400395 MAP2K2 soft tissue,liver,other,neoplasm c.979A>G p.N327D 19:4097284-4097284 3
11 COSM101413162 MAP2K2 soft tissue,liver,other,neoplasm c.688A>G p.N230D 19:4097284-4097284 3
12 COSM106234905 FBXO11 soft tissue,liver,other,neoplasm c.169+4733C>T p.? 2:47803462-47803462 3
13 COSM145029907 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.277A>G p.K93E 17:7675218-7675218 0
14 COSM122867930 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.12A>C p.Q4H 17:7675204-7675204 0
15 COSM144053685 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.637G>A p.E213K 17:7674861-7674861 0
16 COSM145024607 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.370T>A p.Y124N 17:7675125-7675125 0
17 COSM144345367 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.553G>A p.E185K 17:7674861-7674861 0
18 COSM143162240 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.10T>A p.Y4N 17:7675125-7675125 0
19 COSM106095757 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
20 COSM106061123 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 0
21 COSM144097034 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.-84A>G p.? 17:7675218-7675218 0
22 COSM144021454 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.548T>G p.L183R 17:7674950-7674950 0
23 COSM144013232 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.563G>A p.G188E 17:7674935-7674935 0
24 COSM93228799 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
25 COSM87897904 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.596G>A p.G199E 17:7674935-7674935 0
26 COSM105627347 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
27 COSM105620091 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.596G>A p.G199E 17:7674935-7674935 0
28 COSM87905987 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
29 COSM122271411 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.200G>A p.G67E 17:7674935-7674935 0
30 COSM112383578 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.408A>C p.Q136H 17:7675204-7675204 0
31 COSM112259728 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
32 COSM142572432 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.277A>G p.K93E 17:7675218-7675218 0
33 COSM144061755 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.-70A>C p.? 17:7675204-7675204 0
34 COSM143163611 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.104T>G p.L35R 17:7674950-7674950 0
35 COSM144193302 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.-70A>C p.? 17:7675204-7675204 0
36 COSM106053056 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.596G>A p.G199E 17:7674935-7674935 0
37 COSM143167205 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.-84A>G p.? 17:7675218-7675218 0
38 COSM142842304 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
39 COSM143384728 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.277A>G p.K93E 17:7675218-7675218 0
40 COSM105766477 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.408A>C p.Q136H 17:7675204-7675204 0
41 COSM105673488 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
42 COSM143950762 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.104T>G p.L35R 17:7674950-7674950 0
43 COSM122393220 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.12A>C p.Q4H 17:7675204-7675204 0
44 COSM145057596 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.553G>A p.E185K 17:7674861-7674861 0
45 COSM143156752 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.119G>A p.G40E 17:7674935-7674935 0
46 COSM111767327 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 0
47 COSM144019934 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.454T>A p.Y152N 17:7675125-7675125 0
48 COSM143984355 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.193G>A p.E65K 17:7674861-7674861 0
49 COSM121875792 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.200G>A p.G67E 17:7674935-7674935 0
50 COSM145137450 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.291A>C p.Q97H 17:7675204-7675204 0

Copy number variations for Anaplastic Large Cell Lymphoma from CNVD:

7 (show all 11)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19994 1 152394403 152431233 Translate TPM3 Anaplastic large cell lymphoma
2 122442 18 56200000 78077248 Loss Anaplastic large cell lymphoma
3 154895 20 49800000 58400000 Gain Anaplastic large cell lymphoma
4 154985 20 5100000 42100000 Gain Anaplastic large cell lymphoma
5 166394 3 101910849 101950501 Translate TFG Anaplastic large cell lymphoma
6 199890 5 4500000 23300000 Gain Anaplastic large cell lymphoma
7 264349 X 64804235 64878518 Translate MSN Anaplastic large cell lymphoma
8 300361 11 128069198 128187521 Translocation FLI1 Anaplastic large cell lymphoma
9 303153 2 29269143 29997936 Translocation ALK Anaplastic large cell lymphoma
10 303499 22 27994016 28026515 Translocation EWSR1 Anaplastic large cell lymphoma
11 304007 5 170747402 170770493 Translocation NPM1 Anaplastic large cell lymphoma

Expression for Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Anaplastic Large Cell Lymphoma.

Pathways for Anaplastic Large Cell Lymphoma

Pathways related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 TNFSF8 TNFRSF8 STAT3 RNF213 PTPRC MUC1
2
Show member pathways
13.63 TNFSF8 TNFRSF8 STAT3 MUC1 JUNB JAK3
3
Show member pathways
13.14 TNFSF8 TNFRSF8 STAT3 MUC1 JUNB JAK3
4
Show member pathways
12.96 TNFSF8 TNFRSF8 STAT3 JUNB JAK3 CSF1R
5 12.61 TRAF1 TFG STAT3 JAK3 CSF1R ALK
6 12.09 TRAF1 PAX5 GZMB CSF1R
7 11.74 TRAF1 TNFRSF8 STAT3 PTPRC PAX5 JUNB
8 11.73 STAT3 MUC1 JUNB JAK3
9 11.65 PTPRC GZMB CD4
10
Show member pathways
11.61 STAT3 JUNB CD4
11 11.6 STAT3 PTPRC CD4
12 11.58 PTPRC CSF1R CD4
13
Show member pathways
11.58 STAT3 JAK3 GZMB CD4
14 11.56 STAT3 PTPRC JAK3
15 11.45 PPID PAX5 CSF1R CD4
16
Show member pathways
11.29 STAT3 JAK3 CSF1R
17 11.23 PTPRC JAK3 CD4
18 10.93 STAT3 NPM1 JUNB JAK3 ALK

GO Terms for Anaplastic Large Cell Lymphoma

Cellular components related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.17 TNFSF8 PTPRC MUC1 CSF1R CD4 ALK

Biological processes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.97 STAT3 PTPRC PPID NPM1 CD4
2 signal transduction GO:0007165 9.97 TRAF1 TNFSF8 TNFRSF8 STAT3 NPM1 CSF1R
3 negative regulation of cell proliferation GO:0008285 9.91 TNFRSF8 STAT3 NPM1 CSF1R ACVRL1
4 regulation of apoptotic process GO:0042981 9.86 TRAF1 JAK3 CLU ALK
5 regulation of cell proliferation GO:0042127 9.8 STAT3 JUNB CLU ALK
6 positive regulation of kinase activity GO:0033674 9.71 CSF1R CD4 ALK
7 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.57 STAT3 JAK3
8 positive regulation of tumor necrosis factor production GO:0032760 9.56 TNFRSF8 STAT3 PTPRC CLU
9 regulation of JAK-STAT cascade GO:0046425 9.55 PTPRC JAK3
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.55 TRAF1 STAT3 NPM1 CLU ALK
11 positive regulation of T cell proliferation GO:0042102 9.54 PTPRC JAK3 CD4
12 interleukin-9-mediated signaling pathway GO:0038113 9.52 STAT3 JAK3
13 regulation of extrinsic apoptotic signaling pathway GO:2001236 9.48 TRAF1 PTPRC
14 microglial cell proliferation GO:0061518 9.46 CSF1R CLU
15 interleukin-21-mediated signaling pathway GO:0038114 9.43 STAT3 JAK3
16 enzyme linked receptor protein signaling pathway GO:0007167 9.4 JAK3 CD4
17 interleukin-15-mediated signaling pathway GO:0035723 9.13 STAT3 JAK3 CD4
18 cytokine-mediated signaling pathway GO:0019221 9.1 STAT3 MUC1 JUNB JAK3 CSF1R CD4

Molecular functions related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.13 STAT3 JAK3 CSF1R
2 protein kinase binding GO:0019901 9.02 STAT3 PTPRC NPM1 CD4 ACVRL1

Sources for Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....